Comprehensive genetic alteration profiling in primary and recurrent glioblastoma

Beth K. Neilsen, Richard Sleightholm, Rodney D McComb, Shakti H. Ramkissoon, Jeffrey S. Ross, Robert J. Corona, Vincent A. Miller, Matthew Cooke, Michele R Aizenberg Ansari

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Glioblastoma (GBM) is heterogeneous and underlying genomic profiles influence evolution, resistance, and therapeutic responses. While extensive knowledge regarding genomic profiling of primary GBM exists, there remains a lack of understanding of genomic differences in recurrent GBM. Methods: We used the FoundationOne® comprehensive genomic profiling assay (CGP) to analyze ten matched primary and recurrent GBM. Genomic alterations (GA) were compared to the cancer database Catalogue of Somatic Mutations in Cancer (COSMIC). Results: All matched tumor pairs demonstrated differences in GA between the primary and recurrence including one resected without any intervening therapy. This suggests that time and/or therapeutic intervention contribute to GA. Although mutations were common to both the primary and recurrence, the percent reads varied substantially suggesting clonal expansions and contractions. For example, EGFR mutations were significantly expanded in three patients, and CNAs were increased in two patients at recurrence. Four genes that were commonly altered in both primary and recurrent GBM were more prevalent in our cohort than reported in COSMIC: CDKN2A (86% vs. 53%) and CDKN2B (86% vs. 54%) deletions, EGFR activating mutation (52% vs. 10%) or amplification (81% vs. 45%), and TERT mutation (95% vs. 51%). Lastly, PI3K pathway activating mutations were also commonly seen in our cohort (67%). Conclusions: CGP revealed that GA identified in GBM changed over time and with treatment. Mutations in TERT, CDKN2A/CDKN2B, EGFR, and PI3K pathway were commonly observed in both primary and recurrent GBM revealing their prognostic and therapeutic potential. This may have important implications for individualized therapies and needs further evaluation.

Original languageEnglish (US)
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Glioblastoma
Mutation
Phosphatidylinositol 3-Kinases
Recurrence
Neoplasms
Therapeutics
Databases
Genes

Keywords

  • EGFR
  • Genomic profiling
  • Glioblastoma
  • Recurrent glioblastoma

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Comprehensive genetic alteration profiling in primary and recurrent glioblastoma. / Neilsen, Beth K.; Sleightholm, Richard; McComb, Rodney D; Ramkissoon, Shakti H.; Ross, Jeffrey S.; Corona, Robert J.; Miller, Vincent A.; Cooke, Matthew; Aizenberg Ansari, Michele R.

In: Journal of Neuro-Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Neilsen, Beth K. ; Sleightholm, Richard ; McComb, Rodney D ; Ramkissoon, Shakti H. ; Ross, Jeffrey S. ; Corona, Robert J. ; Miller, Vincent A. ; Cooke, Matthew ; Aizenberg Ansari, Michele R. / Comprehensive genetic alteration profiling in primary and recurrent glioblastoma. In: Journal of Neuro-Oncology. 2018.
@article{b5776571dbd84d749a0483c4c1d2cbe1,
title = "Comprehensive genetic alteration profiling in primary and recurrent glioblastoma",
abstract = "Introduction: Glioblastoma (GBM) is heterogeneous and underlying genomic profiles influence evolution, resistance, and therapeutic responses. While extensive knowledge regarding genomic profiling of primary GBM exists, there remains a lack of understanding of genomic differences in recurrent GBM. Methods: We used the FoundationOne{\circledR} comprehensive genomic profiling assay (CGP) to analyze ten matched primary and recurrent GBM. Genomic alterations (GA) were compared to the cancer database Catalogue of Somatic Mutations in Cancer (COSMIC). Results: All matched tumor pairs demonstrated differences in GA between the primary and recurrence including one resected without any intervening therapy. This suggests that time and/or therapeutic intervention contribute to GA. Although mutations were common to both the primary and recurrence, the percent reads varied substantially suggesting clonal expansions and contractions. For example, EGFR mutations were significantly expanded in three patients, and CNAs were increased in two patients at recurrence. Four genes that were commonly altered in both primary and recurrent GBM were more prevalent in our cohort than reported in COSMIC: CDKN2A (86{\%} vs. 53{\%}) and CDKN2B (86{\%} vs. 54{\%}) deletions, EGFR activating mutation (52{\%} vs. 10{\%}) or amplification (81{\%} vs. 45{\%}), and TERT mutation (95{\%} vs. 51{\%}). Lastly, PI3K pathway activating mutations were also commonly seen in our cohort (67{\%}). Conclusions: CGP revealed that GA identified in GBM changed over time and with treatment. Mutations in TERT, CDKN2A/CDKN2B, EGFR, and PI3K pathway were commonly observed in both primary and recurrent GBM revealing their prognostic and therapeutic potential. This may have important implications for individualized therapies and needs further evaluation.",
keywords = "EGFR, Genomic profiling, Glioblastoma, Recurrent glioblastoma",
author = "Neilsen, {Beth K.} and Richard Sleightholm and McComb, {Rodney D} and Ramkissoon, {Shakti H.} and Ross, {Jeffrey S.} and Corona, {Robert J.} and Miller, {Vincent A.} and Matthew Cooke and {Aizenberg Ansari}, {Michele R}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11060-018-03070-2",
language = "English (US)",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Comprehensive genetic alteration profiling in primary and recurrent glioblastoma

AU - Neilsen, Beth K.

AU - Sleightholm, Richard

AU - McComb, Rodney D

AU - Ramkissoon, Shakti H.

AU - Ross, Jeffrey S.

AU - Corona, Robert J.

AU - Miller, Vincent A.

AU - Cooke, Matthew

AU - Aizenberg Ansari, Michele R

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Glioblastoma (GBM) is heterogeneous and underlying genomic profiles influence evolution, resistance, and therapeutic responses. While extensive knowledge regarding genomic profiling of primary GBM exists, there remains a lack of understanding of genomic differences in recurrent GBM. Methods: We used the FoundationOne® comprehensive genomic profiling assay (CGP) to analyze ten matched primary and recurrent GBM. Genomic alterations (GA) were compared to the cancer database Catalogue of Somatic Mutations in Cancer (COSMIC). Results: All matched tumor pairs demonstrated differences in GA between the primary and recurrence including one resected without any intervening therapy. This suggests that time and/or therapeutic intervention contribute to GA. Although mutations were common to both the primary and recurrence, the percent reads varied substantially suggesting clonal expansions and contractions. For example, EGFR mutations were significantly expanded in three patients, and CNAs were increased in two patients at recurrence. Four genes that were commonly altered in both primary and recurrent GBM were more prevalent in our cohort than reported in COSMIC: CDKN2A (86% vs. 53%) and CDKN2B (86% vs. 54%) deletions, EGFR activating mutation (52% vs. 10%) or amplification (81% vs. 45%), and TERT mutation (95% vs. 51%). Lastly, PI3K pathway activating mutations were also commonly seen in our cohort (67%). Conclusions: CGP revealed that GA identified in GBM changed over time and with treatment. Mutations in TERT, CDKN2A/CDKN2B, EGFR, and PI3K pathway were commonly observed in both primary and recurrent GBM revealing their prognostic and therapeutic potential. This may have important implications for individualized therapies and needs further evaluation.

AB - Introduction: Glioblastoma (GBM) is heterogeneous and underlying genomic profiles influence evolution, resistance, and therapeutic responses. While extensive knowledge regarding genomic profiling of primary GBM exists, there remains a lack of understanding of genomic differences in recurrent GBM. Methods: We used the FoundationOne® comprehensive genomic profiling assay (CGP) to analyze ten matched primary and recurrent GBM. Genomic alterations (GA) were compared to the cancer database Catalogue of Somatic Mutations in Cancer (COSMIC). Results: All matched tumor pairs demonstrated differences in GA between the primary and recurrence including one resected without any intervening therapy. This suggests that time and/or therapeutic intervention contribute to GA. Although mutations were common to both the primary and recurrence, the percent reads varied substantially suggesting clonal expansions and contractions. For example, EGFR mutations were significantly expanded in three patients, and CNAs were increased in two patients at recurrence. Four genes that were commonly altered in both primary and recurrent GBM were more prevalent in our cohort than reported in COSMIC: CDKN2A (86% vs. 53%) and CDKN2B (86% vs. 54%) deletions, EGFR activating mutation (52% vs. 10%) or amplification (81% vs. 45%), and TERT mutation (95% vs. 51%). Lastly, PI3K pathway activating mutations were also commonly seen in our cohort (67%). Conclusions: CGP revealed that GA identified in GBM changed over time and with treatment. Mutations in TERT, CDKN2A/CDKN2B, EGFR, and PI3K pathway were commonly observed in both primary and recurrent GBM revealing their prognostic and therapeutic potential. This may have important implications for individualized therapies and needs further evaluation.

KW - EGFR

KW - Genomic profiling

KW - Glioblastoma

KW - Recurrent glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=85058071352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058071352&partnerID=8YFLogxK

U2 - 10.1007/s11060-018-03070-2

DO - 10.1007/s11060-018-03070-2

M3 - Article

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -